Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – ...

Teladoc Health, Inc. faces challenges with low utilization and operating losses, but a new CEO aims to revitalize the company ...

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Ultimately, these developments have translated into a broad slowdown that helps explain Teladoc's stock-price weakness. In the third quarter, Teladoc's revenue declined by 3% year over year ...

Oppenheimer maintained Teladoc Health with an Outperform, but lowered the price target from $21 to $17 following the print. According to Benzinga Pro, the stock is down on heavy trading volume ...

Was Teladoc Health (NYSE ... Long-term investors with an appetite for risk should consider the stock, especially as its share price remains below its pre-pandemic levels. Risk-averse investors ...

At the time of writing, the stock is down a disastrous 57% this year amid large recurring financial losses and weak growth.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...